Anzeige
Erschienen in:
01.03.2015 | Antibodies and Other Biological Treatments (M Bigal, Section Editor)
TEV-48125: a Review of a Monoclonal CGRP Antibody in Development for the Preventive Treatment of Migraine
Erschienen in: Current Pain and Headache Reports | Ausgabe 3/2015
Einloggen, um Zugang zu erhaltenAbstract
Calcitonin gene-related peptide (CGRP) is a 37-amino-acid neuropeptide whose involvement in migraine pathophysiology is well established. Originally migraine was believed to be a disease of the vasculature, but research has highlighted this to be a disease of the brain with CGRP playing an important role. While targeting CGRP using small molecule antagonists against the receptor has been effective, long-term use of these agents has not been possible due to safety concerns and/or formulation challenges. Recent advances in therapeutic antibodies have opened up new possibilities for treatment of migraine. TEV-48125 is one of four monoclonal antibodies targeting CGRP or its receptors, currently in development for the preventive treatment of migraine. This article discusses the in vitro and in vivo pharmacology of TEV-48125 as well as highlighting its safety profile through the six Phase 1 studies that have been conducted. Finally, the current state of development and future studies for TEV-48125 will be reviewed.